Table 4 –
Explant Characteristics for Patients AFP ≥100ng/mL
| Variable | HCV N = 650 | HBV N = 49 | EtOH N = 39 | NAFLD N = 44 | Autoimmune N = 18 | Other N = 90 | p-value |
|---|---|---|---|---|---|---|---|
| Number of Tumors | 0.039* | ||||||
| Solitary | 286 (44.0%) | 33 (67.3%) | 14 (35.9%) | 19 (43.2%) | 9 (50.0%) | 41 (45.6%) | |
| Multiple | 364 (56.0%) | 16 (32.7%) | 25 (64.1%) | 25 (56.8%) | 9 (50.0%) | 49 (54.4%) | |
| Macrovascular Invasion | 0.240 | ||||||
| No | 630 (96.9%) | 47 (95.9%) | 37 (94.9%) | 41 (93.2%) | 18 (100.0%) | 83 (92.2%) | |
| Yes | 20 (3.1%) | 2 (4.1%) | 2 (5.1%) | 3 (6.8%) | 0 (0.0%) | 7 (7.8%) | |
| Poorly Differentiated | 0.150 | ||||||
| No | 570 (87.7%) | 45 (91.8%) | 29 (74.4%) | 37 (84.1%) | 16 (88.9%) | 75 (83.3%) | |
| Yes | 80 (12.3%) | 4 (8.2%) | 10 (25.6%) | 7 (15.9%) | 2 (11.1%) | 15 (16.7%) | |
| Poor Prognosis‡ | 0.019* | ||||||
| No | 252 (38.8%) | 29 (59.2%) | 9 (23.1%) | 18 (40.9%) | 9 (50.0%) | 34 (37.8%) | |
| Yes | 398 (61.2%) | 20 (40.8%) | 30 (76.9%) | 26 (59.1%) | 9 (50.0%) | 56 (62.2%) | |
| Within Milan Criteria | 0.620 | ||||||
| No | 213 (32.8%) | 12 (24.5%) | 12 (30.8%) | 17 (38.6%) | 7 (38.9%) | 34 (37.8%) | |
| Yes | 437 (67.2%) | 37 (75.5%) | 27 (69.2%) | 27 (61.4%) | 11 (61.1%) | 56 (62.2%) | |
| Max Tumor Size (cm), median (IQR) | 2.6 (2, 3.7) | 2.5 (1.3, 3.5) | 2.2 (1.7, 3.4) | 3.2 (2.1, 4.3) | 3.1 (2.5, 3.5) | 3 (2, 4.2) | 0.040* |
*
Statistically significant at the alpha = 0.05 level
‡
Aggregate variable including the presence of: multiple tumors, macrovascular invasion, or poor tumor differentiation